Editpep
Editpep develops a class of peptides designed to deliver CRISPR enzymes effectively, enhancing the precision of gene editing applications. This technology addresses the challenge of efficient and targeted delivery in CRISPR therapies, improving the potential for therapeutic outcomes.
- Biotechnology
Funding
Raised to date
$8.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
CRISPR-based gene therapies face challenges in delivering the Cas enzymes efficiently and specifically to target cells, which limits therapeutic efficacy and can lead to off-target effects. Traditional delivery methods often suffer from low transfection rates and potential immunogenicity.
Solution
Editpep is developing a novel peptide-based delivery platform designed to enhance the precision and efficiency of CRISPR-Cas enzyme delivery. These peptides facilitate the transport of CRISPR components into cells, improving gene editing outcomes. The platform aims to overcome the limitations of existing delivery methods by providing a more targeted and biocompatible approach. By improving delivery efficiency, Editpep's technology seeks to increase the therapeutic potential of CRISPR-based therapies while minimizing off-target effects.
Target Audience
The primary target audience includes researchers and pharmaceutical companies developing CRISPR-based gene therapies.
Features
- Peptide-mediated delivery of CRISPR-Cas enzymes
- Enhanced cellular uptake and targeted delivery
- Improved gene editing efficiency
- Reduced off-target effects
- Biocompatible delivery platform